# Impact of Atorvastatin on Prostate Cancer Progression During ADT

> **NCT04026230** · PHASE3 · UNKNOWN · sponsor: **Tampere University Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Metastatic Prostate Cancer
- Recurrent Prostate Cancer

## Interventions

- **DRUG:** Atorvastatin 80mg
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT04026230
- **Lead sponsor:** Tampere University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2022-10-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04026230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04026230, "Impact of Atorvastatin on Prostate Cancer Progression During ADT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04026230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*